- Home
- SRV vs SGMT Comparison
SRV vs SGMT Comparison
Compare SRV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- SGMT
- Stock Information
- Founded
- SRV 2007
- SGMT 2006
- Country
- SRV United States
- SGMT United States
- Employees
- SRV N/A
- SGMT N/A
- Industry
- SRV Finance Companies
- SGMT
- Sector
- SRV Finance
- SGMT
- Exchange
- SRV Nasdaq
- SGMT Nasdaq
- Market Cap
- SRV 146.5M
- SGMT 159.0M
- IPO Year
- SRV N/A
- SGMT 2023
- Fundamental
- Price
- SRV $49.50
- SGMT $4.13
- Analyst Decision
- SRV
- SGMT Buy
- Analyst Count
- SRV 0
- SGMT 6
- Target Price
- SRV N/A
- SGMT $23.00
- AVG Volume (30 Days)
- SRV 33.9K
- SGMT 1.2M
- Earning Date
- SRV 01-01-0001
- SGMT 11-13-2024
- Dividend Yield
- SRV 13.38%
- SGMT N/A
- EPS Growth
- SRV N/A
- SGMT N/A
- EPS
- SRV N/A
- SGMT N/A
- Revenue
- SRV N/A
- SGMT N/A
- Revenue This Year
- SRV N/A
- SGMT N/A
- Revenue Next Year
- SRV N/A
- SGMT N/A
- P/E Ratio
- SRV N/A
- SGMT N/A
- Revenue Growth
- SRV N/A
- SGMT N/A
- 52 Week Low
- SRV $30.73
- SGMT $2.39
- 52 Week High
- SRV $44.30
- SGMT $18.90
- Technical
- Relative Strength Index (RSI)
- SRV 73.89
- SGMT 41.82
- Support Level
- SRV $45.57
- SGMT $4.06
- Resistance Level
- SRV $46.44
- SGMT $7.38
- Average True Range (ATR)
- SRV 0.92
- SGMT 0.63
- MACD
- SRV 0.45
- SGMT -0.11
- Stochastic Oscillator
- SRV 93.20
- SGMT 2.11
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).